Dinutuximab beta:
EMA Approved
- Dinutuximab-beta is a monoclonal anti – GD2 antibody indicated for the treatment of newly diagnosed, relapsed and refractory high-risk neuroblastoma.
- It is a form of immunotherapy which binds to GD-2, which is over-expressed in neuroblastoma cells and induces antibody and complement-mediated cytotoxicity to eradicate tumor cells.
For any medical enquiry,
Contact us at +91 9591736262 or
Email us at info@sayretherapeutics.com